Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

National Center for Rehabilitative Auditory Research (NCRAR)

Quick Links
Veterans Crisis Line Badge
My healthevet badge

NCRAR Monthly Seminar Series - CEU Details

The current month's seminar info and CEU documents are below (see highlighted section when you scroll to the bottom of the page).

Date: Thursday, May 9, 2024

Time: 12-1pm (Pacific)

Location: VA Portland Health Care System, NCRAR (Virtual)

John Lee, AuD, PhD, Postdoctoral fellow at the National Institute on Deafness and Other Communication Disorders (NIDCD) at the National Institutes of Health

Title: Cisplatin-Induced Vestibulotoxicity in a Mouse Model and in Human Temporal Bones

Abstract: Despite its effectiveness in treating cancer, cisplatin can induce cochleotoxicity in up to 50-60% of patients. However, the vestibulotoxic potential of cisplatin remains unclear. Reported incidences are highly variable, vestibular symptoms are often underappreciated, and objective vestibular testing is often limited to assessment of horizontal semicircular canal function. Our lab previously developed and optimized a multi-cycle model of cisplatin administration in mice that results in hearing loss similar to that observed clinically. The purpose of this study is to characterize the functional and morphological consequences of cisplatin on the vestibular periphery in this mouse model. 

Our results demonstrate cisplatin’s potential to adversely and differentially affect the vestibular end organs, and they suggest that the vestibulotoxic potential of cisplatin is likely underestimated clinically. The saccule was uniquely susceptible in our mouse model, suggesting that it may be possible to screen for cisplatin-induced vestibulotoxicity by testing saccular function. Current efforts are aimed at utilizing the NIDCD National Temporal Bone Registry to characterize vestibular morphology in temporal bones from cisplatin-treated patients. 

Learner Outcomes: Upon completion of this session, participants will be able to:

• Describe the adverse effects of cisplatin on the vestibular system.
• Identify the specific limitations in our current understanding of cisplatin-induced vestibulotoxicity.
• Discuss the utilization of animal models to guide development and implementation of vestibulotoxicity monitoring protocols.

Disclosure statements: Dr. Lee does not have any financial or non-financial relationships to disclose. 

*IMPORTANT DETAILS: The seminar will be broadcast via Microsoft Teams

To register and receive a Teams invitation, you must contact Marianne Pierson at before 5 p.m. on Wednesday, May 8th, and she will send you an email invitation with a Microsoft Teams link.

Once you have a Microsoft Teams invitation, please see the instructions for joining below at the time of the call:
1. Click on the “Join Microsoft Teams Meeting” link in the Outlook invitation for the seminar (in the Outlook calendar)
2. Click on “Join now," and mute your microphone.
3. Alternately, you can simply call the telephone number listed below the "Join Microsoft Teams Meeting" link. Note: MUTE your phone; do not place your phone on hold.

CEUs: If you wish to receive ASHA CEUs for watching the seminar, please click on the link below to submit your evaluation:

 ASHA CEU Evaluation (link)  

You will need to submit your CEU evaluation within 5 business days (April 19th) in order to receive credit. Contact Marianne Pierson at with questions. 

NCRAR is approved by the American Speech-Language Hearing Association to offer 0.1 CEU for this continuing education activity (Advanced level, Professional Area).